TuHURA Biosciences, Inc./NV Logo

TuHURA Biosciences, Inc./NV

Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.

HURA | US

Overview

Corporate Details

ISIN(s):
US49720K1016
LEI:
Country:
United States of America
Address:
10500 UNIVERSITY CENTER DR., 33612 TAMPA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company focused on developing novel technologies and therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's core mission is to address the challenges of treatment resistance in cancer patients. Its pipeline is built upon distinct technology platforms, including the IMMUNE FX (IFX) innate immune agonist, designed to enhance the efficacy of existing and new cancer treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TuHURA Biosciences, Inc./NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TuHURA Biosciences, Inc./NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TuHURA Biosciences, Inc./NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB

Talk to a Data Expert

Have a question? We'll get back to you promptly.